- Home
- QURE vs OCUL Comparison
QURE vs OCUL Comparison
Compare QURE & OCUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QURE | OCUL |
|---|---|---|
| Founded | 1998 | 2006 |
| Country | Netherlands | United States |
| Employees | N/A | 274 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | QURE | OCUL |
|---|---|---|
| Price | $25.30 | $10.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $58.55 | $22.56 |
| AVG Volume (30 Days) | 1.7M | ★ 4.6M |
| Earning Date | 02-26-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $15,751,000.00 | ★ $55,783,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $142.93 | $11.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.76 | $5.79 |
| 52 Week High | $71.50 | $16.44 |
Technical Indicators
Market Signals| Indicator | QURE | OCUL |
|---|---|---|
| Relative Strength Index (RSI) | 55.22 | 40.42 |
| Support Level | $21.64 | $11.03 |
| Resistance Level | $25.80 | $11.55 |
| Average True Range (ATR) | 1.74 | 0.83 |
| MACD | 0.47 | -0.03 |
| Stochastic Oscillator | 53.94 | 27.04 |
Price Performance
Historical ComparisonAbout QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About OCUL Ocular Therapeutix Inc.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.